Clinical and Economic Impact of Expanded TPMT Testing to Prevent Thiopurine‐Induced Myelosuppression in Australia: A Budget Impact Analysis

ABSTRACT Testing thiopurine methyltransferase (TPMT) enzyme activity or genotype prior to thiopurine prescribing is recommended to reduce the risk of moderate to severe—and potentially fatal—myelosuppression in poor or intermediate TPMT metabolizers. Despite this, only about one‐third of individuals...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Bella D. Ianni, Mohammad Afshar Ali, Chin Hang Yiu, Edwin C. K. Tan, Christine Y. Lu
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Wiley 2026-02-01
Цуврал:	Clinical and Translational Science
Нөхцлүүд:	healthcare costs pharmacogenetic testing pharmacogenetics pharmacogenomics PLIDA precision medicine
Онлайн хандалт:	https://doi.org/10.1111/cts.70389
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!